Novogen - Raging buy, page-2

Here is the other article:

http://biz.yahoo.com/djus/020827/1158000436_2.html

Dow Jones Business News
Novagen Unit, Yale University In Services Pact
Tuesday August 27, 11:58 am ET

WASHINGTON -(Dow Jones)- Novogen Ltd.'s Marshall Edwards Inc. (London:MSH.L - News) entered a service agreement with Yale University's Medical School following the school's discovery that Edwards' phenoxodiol fights ovarian cancer cells.

ADVERTISEMENT


Terms of the agreement weren't provided.

In a press release Tuesday, the pharmaceutical company said it will arrange a phase II clinical trial at Yale in patients with advanced ovarian cancer. The university will conduct the multi-center trial in conjunction with an Australian university hospital.

The Yale research team found that phenoxodiol kills all ovarian cancer cells, Novogen said.

Marshall Edwards, which trades on the alternative investment market of the London Stock Exchange (London:LSE.L - News), is 95% owned by Australian pharmaceutical company Novogen Ltd. Phenoxodiol is the first anticancer drug candidate in development by Marshall, established by Novogen as a commercial vehicle for Novogen's anticancer drug technology.

In recent Nasdaq trading, Novogen American depositary shares changed hands up 70 cents or 20.3% to $4.15 on volume of 64,000 shares. Average daily volume of just 6,430 shares. Novogen ADS, which reached a year low of $1.98 Sept. 21, touched a 52 week high of $9.37 on April 8.

Company Web site: http://www.marshalledwardsinc.com

Company Web site: http://www.novogen.com

-James McDermott; Dow Jones Newswires; 201-938-5400